Ge Healthcare patents expiration
1. Myoview patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549999 | GE HEALTHCARE | Radiopharmaceutical composition |
Mar, 2030
(6 years from now) | |
Drugs and Companies using TECHNETIUM TC-99M TETROFOSMIN KIT ingredient
Market Authorisation Date: 09 February, 1996
Treatment: NA
Dosage: INJECTABLE;INJECTION
More Information on Dosage
MYOVIEW family patents
2. Vizamyl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7351401 | GE HEALTHCARE | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition |
Jan, 2023
(8 months ago) | |
| US8236282 | GE HEALTHCARE | Benzothiazole derivative compounds, compositions and uses |
May, 2024
(7 months from now) | |
| US7270800 | GE HEALTHCARE | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
Sep, 2025
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8691185 | GE HEALTHCARE | Benzothiazole derivative compounds, compositions and uses |
Jan, 2023
(8 months ago) | |
| US8916131 | GE HEALTHCARE | Radiopharmaceutical composition |
Sep, 2028
(4 years from now) | |
Drugs and Companies using FLUTEMETAMOL F-18 ingredient
Market Authorisation Date: 25 October, 2013
Treatment: Diagnostic radioimaging
Dosage: INJECTABLE;INTRAVENOUS
More Information on Dosage
VIZAMYL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic